Expertise in
12
conditions

Eric S. Thervet

Paris, FR 
Expertise in
12
conditions
Paris, FR 

Overview

Eric Thervet practices practicing medicine in Paris, France.

Mr. Thervet is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Chronic Kidney Disease, Acute Kidney Failure, Glomerulonephritis, Henoch-Schonlein Purpura, and Kidney Transplant.

He is actively involved in clinical research, co-authoring 146 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Paris, France
Other Locations
Boulogne-billancourt, France
Georges, France
Villejuif, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal Function
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal Function
Enrollment Status: Active_not_recruiting
Publish Date: June 04, 2026
Intervention Type: Drug
Study Drug: Atrasentan
Study Phase: Phase 3
A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients With Primary FSGS
A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients With Primary FSGS
Enrollment Status: Completed
Publish Date: April 17, 2026
Intervention Type: Drug
Study Drugs: Sparsentan, Irbesartan
Study Phase: Phase 3
View 1 Less Clinical Trial

146 Total Publications

Anti-CD38/Anti-CD20 Rescue Therapy for Posttransplant Recurrent FSGS.
Anti-CD38/Anti-CD20 Rescue Therapy for Posttransplant Recurrent FSGS.
Journal: Kidney international reports
Published: February 18, 2026

Frequently Asked Questions about Eric S. Thervet

Is Eric S. Thervet a top-rated expert for Kidney Transplant?

MediFind is an objective health platform that identifies experts based on real-world data. Eric S. Thervet is classified as an Distinguished expert for Kidney Transplant, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Eric S. Thervet participate in research or clinical trials?

Yes. Eric S. Thervet has published 146 articles and abstracts on conditions like Kidney Transplant. You can view a list of Eric S. Thervet's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Thervet's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 52 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile